Developing and Validating a Stability- Indicating Ultra Performance Liquid Chromatography Method for the Concurrent Measurement of Estradiol and Dydrogesterone in Bulk and Tablet Doses

Pharmacovigilance (PV) is the science of drug safety, now established as a separate discipline driven by modern technologies such as digital health tools, big data, artificial intelligence (AI), and machine learning (ML). Legacy PV methods relied on manual reporting and spontaneous submissions of adverse drug reactions (ADRs), but these were hindered by delays in submissions, signal detection, and data quality issues. Emerging technologies such as AI, digital health, and big data play a critical role in drug safety and risk mitigation. Digital health tools, including wearable monitors, patient engagement modules, and electronic health records, generate Real- World Data that help healthcare professionals track patient reactions to drugs over extended periods, providing insights into genomics, vitals, and ADRs. Big data allows PV practitioners to handle complex, heterogeneous datasets, including patient reviews, which are analyzed using natural language processing to extract insights from social media, reports, and clinical data. ML algorithms automate signal detection, predictive modeling, and casualty assessment, significantly improving the speed and accuracy of ADR identification. Technologies such as AI-driven platforms (e.g., World Health Organization VigiBase and Food and Drug Administration Sentinel initiative) demonstrate how large-scale, real-time data can enhance risk signal identification, while digital health devices assist in monitoring patient vitals for early risk detection. Despite these advancements, challenges persist, including ethical concerns, data inoperability, algorithm bias, and regulatory issues. This review underscores the need for global collaboration, standardized reporting methods, and robust regulatory guidelines to address these challenges. Emerging technologies like the internet of medical things pave the way for personalized and ML-driven predictive PV.

Authors

Publication Details

Journal
Asian Journal of Pharmaceutics
Published
2025-03-01
DOI
https://doi.org/10.22377/ajp.v19i01.6078
Primary Topic
Analytical Methods in Pharmaceuticals
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Developing and Validating a Stability- Indicating Ultra Performance Liquid Chromatography Method for the Concurrent Measurement of Estradiol and Dydrogesterone in Bulk and Tablet Doses

Giri Prasad Gorumutchu
Asian Journal of Pharmaceutics
Analytical Methods in Pharmaceuticals
article

Developing and Validating a Stability- Indicating Ultra Performance Liquid Chromatography Method for the Concurrent Measurement of Estradiol and Dydrogesterone in Bulk and Tablet Doses

Giri Prasad Gorumutchu
article en

Abstract

Pharmacovigilance (PV) is the science of drug safety, now established as a separate discipline driven by modern technologies such as digital health tools, big data, artificial intelligence (AI), and machine learning (ML). Legacy PV methods relied on manual reporting and spontaneous submissions of adverse drug reactions (ADRs), but these were hindered by delays in submissions, signal detection, and data quality issues. Emerging technologies such as AI, digital health, and big data play a critical role in drug safety and risk mitigation. Digital health tools, including wearable monitors, patient engagement modules, and electronic health records, generate Real- World Data that help healthcare professionals track patient reactions to drugs over extended periods, providing insights into genomics, vitals, and ADRs. Big data allows PV practitioners to handle complex, heterogeneous datasets, including patient reviews, which are analyzed using natural language processing to extract insights from social media, reports, and clinical data. ML algorithms automate signal detection, predictive modeling, and casualty assessment, significantly improving the speed and accuracy of ADR identification. Technologies such as AI-driven platforms (e.g., World Health Organization VigiBase and Food and Drug Administration Sentinel initiative) demonstrate how large-scale, real-time data can enhance risk signal identification, while digital health devices assist in monitoring patient vitals for early risk detection. Despite these advancements, challenges persist, including ethical concerns, data inoperability, algorithm bias, and regulatory issues. This review underscores the need for global collaboration, standardized reporting methods, and robust regulatory guidelines to address these challenges. Emerging technologies like the internet of medical things pave the way for personalized and ML-driven predictive PV.

Asian Journal of PharmaceuticsVol. 19(01)
Openalex Percentile: Top 91%
Analytical Methods in Pharmaceuticals
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Developing and Validating a Stability- Indicating Ultra Performance Liquid Chromatography Method for the Concurrent Measurement of Estradiol and Dydrogesterone in Bulk and Tablet Doses — Giri Prasad Gorumutchu · Asian Journal of Pharmaceutics (2025) | TGRS Research Map | TGRS